6) In 2017-2019, WIV constructed and characterized novel SARS-like coronaviruses at biosafety level 2, a biosafety level patently inadequate for work with enhanced potential pandemic pathogens and patently inadequate to contain a virus having transmission properties of SARS-CoV-2

— Richard H. Ebright (@R_H_Ebright) September 5, 2022